CD1-restricted adaptive immune responses to Mycobacteria in human group 1 CD1 transgenic mice

DSpace/Manakin Repository

CD1-restricted adaptive immune responses to Mycobacteria in human group 1 CD1 transgenic mice

Citable link to this page

 

 
Title: CD1-restricted adaptive immune responses to Mycobacteria in human group 1 CD1 transgenic mice
Author: Felio, Kyrie; Nguyen, Hanh; Dascher, Christopher C.; Choi, Hak-Jong; Colmone, Angela; Wang, Chyung-Ru; Li, Sha; Zimmer, Michael I.; Moody, D Branch; Brenner, Michael Barry

Note: Order does not necessarily reflect citation order of authors.

Citation: Felio, Kyrie, Hanh Nguyen, Christopher C. Dascher, Hak-Jong Choi, Sha Li, Michael I. Zimmer, Angela Colmone, D. Branch Moody, Michael B. Brenner, and Chyung-Ru Wang. 2009. CD1-restricted adaptive immune responses to in human group 1 CD1 transgenic mice. Journal of Experimental Medicine 206(11): 2497-2509.
Full Text & Related Files:
Abstract: Group 1 CD1 (CD1a, CD1b, and CD1c)–restricted T cells recognize mycobacterial lipid antigens and are found at higher frequencies in Mycobacterium tuberculosis (Mtb)–infected individuals. However, their role and dynamics during infection remain unknown because of the lack of a suitable small animal model. We have generated human group 1 CD1 transgenic (hCD1Tg) mice that express all three human group 1 CD1 isoforms and support the development of group 1 CD1–restricted T cells with diverse T cell receptor usage. Both mycobacterial infection and immunization with Mtb lipids elicit group 1 CD1–restricted Mtb lipid–specific T cell responses in hCD1Tg mice. In contrast to CD1d-restricted NKT cells, which rapidly respond to initial stimulation but exhibit anergy upon reexposure, group 1 CD1–restricted T cells exhibit delayed primary responses and more rapid secondary responses, similar to conventional T cells. Collectively, our data demonstrate that group 1 CD1–restricted T cells participate in adaptive immune responses upon mycobacterial infection and could serve as targets for the development of novel Mtb vaccines.
Published Version: doi:10.1084/jem.20090898
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768849/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:11181056
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters